The story of the erectile dysfunction drug presents a complex picture for investors. While the initial introduction generated massive returns, the end of its patent opened the floodgates to off-brand versions, dramatically reducing market share. This presents a particular dilemma for firms depending on related blockbuster medications, suggesting th

The legacy of Viagra, and its parent company copyright, presents a intriguing case study for investors. Originally a blockbuster drug, yielding billions in income, its intellectual property lapse created a flood of knock-off medications, significantly diminishing its position . While certain pharmaceutical companies may attempt to capitalize on mal